Enfermedad cardiovascular, el cáncer y las fracturas | 25 AGO 04
Estrógenos conjugados equinos en mujeres postmenopáusicas con histerectomía
Los beneficios incluyen la mejoría en los sofocos y en la atrofia vaginal y la prevención y el tratamiento de la osteoporosis.
Autor: Dres. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA Fuente: Fred Hutchinson Cancer Research Center, Seattle, Wash 98109-1024, USA  JAMA. 2004 Apr 14;291(14):1701-12.
INDICE:  1. Desarrollo | 2. Resultados | 3. Comentario | 4. Bibliografía

1. Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63. MEDLINE

2. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program follow-up study. Circulation. 1987;75:1102-1109. ABSTRACT

3. Grady D, Rueben SB, Pettiti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037. MEDLINE

4. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med. 1991;151:67-72. ABSTRACT

5. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265:1985-1990. ABSTRACT

6. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997;350:1047-1059. MEDLINE

7. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109. MEDLINE

8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333. ABSTRACT/FULL TEXT

9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613. MEDLINE

10. Hays J, Hunt JR, Hubbel A, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13(9 suppl):S18-S77.

11. Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy [letter]. JAMA. 1997;278:477. MEDLINE

12. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003;13:S5-S17. MEDLINE

13. Curb D, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13(9 suppl):S122-S128. | MEDLINE

14. Freedman LS, Anderson G, Kipnis V, et al. Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. Control Clin Trials. 1996;17:509-525. MEDLINE

15. Cox DR. Regression analysis and life tables. J R Stat Soc. 1972;34:187-220.

16. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-446. MEDLINE

17. NIH/NHLBI News Release. Statement from Barbara Alving, MD, Director of the Women's Health Initiative and Acting Director of the National Heart, Lung, and Blood Institute. Available at: http://www.nhlbi.nih.gov/new/press/04-03-02.htm. Accessed March 5, 2004.

18. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13(9 suppl):S78-S86. MEDLINE

19. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol. 1995;85:6-10. ABSTRACT

20. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529. MEDLINE

21. Waters DD, Alderman EL, Has J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432-2440. ABSTRACT

22. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG. 2002;109:1056-1062. MEDLINE

23. ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet. 2002;360:2001-2008. MEDLINE

24. Hodis HN, Mack WJ, Azen SP, et al, for the Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535-545. ABSTRACT

25. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534. ABSTRACT

26. Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57. ABSTRACT

27. Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684. ABSTRACT

28. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen/progestin Replacement Study (HERS). Circulation. 2001;103:638-642. ABSTRACT

29. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249. ABSTRACT

30. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913. MEDLINE

31. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-1297. ABSTRACT

32. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738. ABSTRACT

33. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122:9-16. ABSTRACT

34. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980;303:1195-1198. ABSTRACT

35. Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocrinol Rev. 2002;23:529-539. FULL TEXT

36. Torgerson DJ, Bell-Seyer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285:2891-2897. ABSTRACT/FULL TEXT

37. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy. JAMA. 2002;288:872-881. ABSTRACT/FULL TEXT

38. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289:3243-3253. ABSTRACT/FULL TEXT

39. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk. J Natl Cancer Inst. 2000;92:328-332. ABSTRACT/FULL TEXT

40. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-427. CrossRef | ISI | MEDLINE

41. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289:3254-3263. ABSTRACT/FULL TEXT

42. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med. 1999;130:262-269. ABSTRACT

43. Hsia J, Barad D, Margolis K, et al, for the Women's Health Initiative Research Group. Usefulness of prior hysterectomy as an independent predictor of Framingham risk score (the Women's Health Initiative). Am J Cardiol. 2003;92:264-269. MEDLINE

44. Hill DA, Weiss NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year following the initial prescription: a population-based study. Am J Obstet Gynecol. 2000;182:270-276. MEDLINE

45. FDA News Release. FDA updates hormone therapy information for postmenopausal women. February 10, 2004. Available at: http://www.fda.gov/bbs/topics/NEWS/2004/NEW01022.html. Accessed March 5, 2004



Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí